Compass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Update

Compass Therapeutics, Inc. (NASDAQ:CMPX) was the recipient of a large decline in short interest during the month of January. As of January 31st, there was short interest totalling 2,750,000 shares, a decline of 13.8% from the January 15th total of 3,190,000 shares. Based on an average daily trading volume, of 1,280,000 shares, the short-interest ratio is presently 2.1 days. Approximately 3.3% of the company’s stock are sold short.

Compass Therapeutics Stock Down 2.0 %

Shares of Compass Therapeutics stock traded down $0.07 during trading on Friday, hitting $3.38. 608,060 shares of the stock were exchanged, compared to its average volume of 1,721,795. The company has a fifty day moving average price of $2.28 and a 200-day moving average price of $1.81. Compass Therapeutics has a 1-year low of $0.76 and a 1-year high of $4.08.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Leerink Partners lowered shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $5.00 to $4.00 in a research note on Friday, November 15th. Leerink Partnrs lowered shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 15th. Jefferies Financial Group lifted their price target on shares of Compass Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Monday, February 10th. D. Boral Capital reiterated a “buy” rating and issued a $32.00 price target on shares of Compass Therapeutics in a research note on Wednesday, January 8th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Compass Therapeutics in a research note on Wednesday, January 8th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, Compass Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $11.17.

Institutional Trading of Compass Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Rhumbline Advisers boosted its holdings in shares of Compass Therapeutics by 3.1% during the 4th quarter. Rhumbline Advisers now owns 129,116 shares of the company’s stock worth $187,000 after buying an additional 3,822 shares during the period. Invesco Ltd. lifted its holdings in shares of Compass Therapeutics by 11.3% during the 4th quarter. Invesco Ltd. now owns 39,483 shares of the company’s stock worth $57,000 after acquiring an additional 4,018 shares during the period. SG Americas Securities LLC increased its position in Compass Therapeutics by 16.6% during the 3rd quarter. SG Americas Securities LLC now owns 38,665 shares of the company’s stock worth $71,000 after purchasing an additional 5,515 shares in the last quarter. Bank of New York Mellon Corp increased its position in Compass Therapeutics by 2.6% during the 4th quarter. Bank of New York Mellon Corp now owns 237,975 shares of the company’s stock worth $345,000 after purchasing an additional 6,041 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in Compass Therapeutics by 31.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 46,942 shares of the company’s stock worth $69,000 after purchasing an additional 11,326 shares in the last quarter. Institutional investors own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.